Rejection By Patent Board For Obviousness-Type Double Patenting Affirmed

(January 23, 2018, 1:38 PM EST) -- WASHINGTON, D.C. — An ex parte re-examination by the Patent Trial and Appeal Board that resulted in the rejection of seven claims of the patented immunosuppressive drug Remicade was not erroneous,...
To view the full article, register now.